Core Insights - Lexeo Therapeutics hosted a fireside chat focusing on a holistic approach to managing PKP2-associated arrhythmogenic cardiomyopathy, featuring insights from leading clinicians in the field [1][2]. Group 1: Company Overview - The call was led by Louis Tamayo, the Chief Financial Officer of Lexeo Therapeutics, indicating the company's commitment to engaging with the medical community [1][2]. - Dr. Eric Adler from Lexeo Therapeutics and Dr. Victoria Parikh from Stanford School of Medicine participated in the discussion, highlighting collaboration with prominent experts in cardiovascular disease [2]. Group 2: Future Expectations - The call included forward-looking statements regarding Lexeo's future expectations and plans, emphasizing the company's strategic direction and potential developments in their therapeutic approaches [3].